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Abstract: Nanomedicines have shown great potential in cancer therapy; in particular, the combina-
tion of chemotherapy and immunotherapy (namely chemoimmunotherapy) that is revolutionizing
cancer treatment. Currently, most nanomedicines for chemoimmunotherapy are still in preclinical
and clinical trials. Lipid-based nanoparticles, the most widely used nanomedicine platform in cancer
therapy, is a promising delivery platform for chemoimmunotherapy. In this review, we introduce
the commonly used immunotherapy agents and discuss the opportunities for chemoimmunother-
apy mediated by lipid-based nanoparticles. We summarize the clinical trials involving lipid-based
nanoparticles for chemoimmunotherapy. We also highlight different chemoimmunotherapy strategies
based on lipid-based nanoparticles such as liposomes, nanodiscs, and lipid-based hybrid nanopar-
ticles in preclinical research. Finally, we discuss the challenges that have hindered the clinical
translation of lipid-based nanoparticles for chemoimmunotherapy, and their future perspectives.
Keywords: chemoimmunotherapy; lipid-based nanoparticles; liposomes; cancer therapy;
immunotherapy
1. Cancer Chemoimmunotherapy
Cancer chemoimmunotherapy is a treatment that utilizes the synergistic benefits of
chemotherapy and immunotherapy. Chemotherapy typically involves the use of con-
ventional cytotoxic drugs and/or novel molecularly targeted agents. On the other hand,
immunotherapy, including the use of immune checkpoint inhibitors, adoptive cell therapy,
cancer vaccines, and cytokines, is a fairly novel type of cancer therapy that uses the pa-
tient’s own immune system to attack cancer cells. We will introduce widely used cancer
immunotherapy strategies and explain the advantages of cancer chemoimmunotherapy
based on the understanding of combination mechanisms.
1.1. Cancer Immunotherapy
Since the first immunotherapy cytokine interferon-α (IFNα) was approved by the U.S.
Food and Drug Administration (FDA) in 1986 for hairy cell leukemia, early-stage cancer
immunotherapy from cytokines to interleukin-2 (IL-2) has shown limited therapeutic ef-
fect with high toxicity [1,2]. This situation was greatly improved when the pioneering
checkpoint inhibitor ipilimumab, a monoclonal antibody (mAb) that targets CTLA4 (cy-
totoxic T-lymphocyte-associated protein 4), was approved for the treatment of advanced
melanoma in 2011 by the FDA, which was featured by Science as the breakthrough of the
year in 2013 [3,4]. Until now, cancer immunotherapy has been shown to be effective in
treating certain cancers and has been approved by the FDA to treat melanoma, non-small
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cell lung cancer (NSCLC), kidney, bladder, head and neck, gastric, hepatocellular, and
cervical cancer [5]. Over the past several years, cancer immunotherapy has been focused on
immunosurveillance mechanisms, including release of tumor-associated antigens, tumor
antigen-presenting cells (APCs), T-cell activation and trafficking, and the role of certain
costimulatory factors (Figure 1) [6–8]. Based upon these mechanisms, cancer immunother-
apy includes the following categories: immune checkpoint inhibitor therapy, adoptive cell
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Figure 1. Cancer-immunity microenvironment affecting responsiveness to immunotherapy Adapted
with permission from [7], Small 2019. CTL, cytotoxic T lymphocyte; DC, dendritic cell; Treg, regulatory
T cell.
1.1.1. Immune Checkpoint I i it r (I I) era
ICI therapy is descri e as t e se f t era e tic a ti ies that interrupt the coin-
hibitory T-cell signaling path ays an unleas a tit r i e res ses [10]. he
develop ent of I Is is a re l ti ar ilest e i t e fiel f i une oncology [11].
Ipilimumab, t r eti TLA-4, was the first ICI approved by the FDA for metastatic
melanoma [3,12]. Following that, anti-programmed death (PD)-1 antibodies (e.g., pem-
brolizumab a d nivolumab) and anti-progra me death ligand-1 (PD-L1) antibodies (e.g.,
atezolizumab and durval ) ere e el e i el se in the treatment of sev-
eral cancer types, including ela a, , re al cell carci a, a ead and neck
squamous cell carcinoma [13–17]. il i t e rece t s ccess f I Is, ore than 3000
clinical trials using ICIs as either a single agent or in combination with c emotherapies are
in progress for ar und 50 cancer types [11,18].
Although ICIs have sh s cc ss i c c r tr t t, l fr cti f tients
could benefit from these treatments because the antitumor immune response is modulated
by several factors [10,19]. The ICIs showed higher responses in patients it certain
biomarkers, res lti i a narrow therapeutic window. Combination strategies (e.g.,
using two ICIs or a combination of an ICI and che otherapy), are thought to iden the
therapeutic window of ICIs.
1.1.2. Adaptive Cel Thera (
ACT, including the use of tu or-infiltr t ), ineered T-ce l
receptors (TCRs) and chi eric a ti r ti e tr t ent
modality in cancer immunotherapy. Compared with ICI therapy, ACT seems to be a more
personalized treatment using autologous T lymphocytes of individual patients.
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TILs extracted from fresh tumor samples or peripheral blood lymphocytes of patients,
containing cluster of differentiation CD4+ and CD8+ T cells, were proven to mediate objec-
tive regression of cancer in patients with metastatic melanoma [20,21]. However, not all
patients have the TILs that can recognize the tumor antigens. Researchers found that T cells
could be collected from patients and engineered to express a TCR that could target a specific
tumor antigen [22]. To generate TCRs, coculturing T cells with tumor APCs and genetic
engineering was used to produce T cells with the desired TCRs [23]. Adoptive transfer of
sorted New York esophageal squamous cell carcinoma-1 (NY-ESO-1) TCR T cells could
specifically recognize tumor antigens and mount productive antitumor cell responses [24].
Both TILs and TCRs require antigen presentation via the major histocompatibility complex
(MHC). In some cancer types, MHC expression is downregulated to escape from the im-
mune system [25]. To solve this problem, CAR was developed. CD19, which is expressed
on B-cell leukemias and lymphomas, was the initial target for CAR T cells [26–29]. In 2017,
the first CAR T-cell therapy was approved by the FDA for the treatment of certain types of
large B-cell lymphoma [30]. Compared with TILs and TCR, CAR T cells could retain their
activity for a long time after one intravenous injection [31]. The clinical success of CAR T
cells has encouraged the recent efforts to engineer other immune cells, such as natural killer
(NK) cells. Recently, CAR NK cells have been explored in clinical trials for the treatment of
several cancer types including B-cell lymphoma (NCT03692767), metastatic solid tumors
(NCT03415100), ovarian cancer (NCT03692637), and prostate cancer (NCT03692663).
Overall, ACT is a more complex and expensive approach for cancer treatment than
other types of immunotherapy. The “off-target” toxic effects caused by expression of
antigens on normal cells has remained a challenge in ACT applications. Appropriate
delivery strategies and more specific antigens are needed for the widespread applications
of ACT.
1.1.3. Cancer Vaccines
Vaccines have been proven to be effective in preventing diseases caused by viruses and
bacteria. However, the development of cancer vaccines is more complicated and difficult
compared with conventional vaccines for infectious diseases. Unlike viruses and bacteria,
cancer cells can camouflage themselves as normal healthy cells. Furthermore, the tumor
antigens between individual patients are quite different and unique [32]. These obstacles
have hindered the development of cancer vaccines. To circumvent these issues, multiple
cancer vaccines are currently being studied, including dendritic cell (DC)-based, nucleic
acid-based, and neoantigen-based vaccines [33–35].
The DC vaccine sipuleucel-T (Provenge®) is the only cancer vaccine to date that
has been approved by the FDA, in 2010, for prostate cancer treatment [36]. DC vaccines
made from patients’ own stimulated DCs could prolong overall survival [37]. Nucleic
acid vaccines, which deliver genes encoding tumor antigens by DNA or mRNA, is a
promising strategy for harnessing the immune system against cancer [38]. Several clinical
trials using plasmid DNA vaccines have demonstrated a good safety profile and the
activation of a broad and specific immune response. However, therapeutic effects appeared
to be modest due to the complicated immunosuppressive mechanisms and the barriers
of nuclear delivery [38–40]. In particular, mRNA is easily degraded by nucleases and
has poor storage stability [41]. Therefore, delivery platforms that increase intracellular
uptake of vaccines to improve targeting effect as well as stability are important for the
development of nucleic acid vaccines. Most recently, neoantigen vaccines have been
investigated to overcome the obstacles in developing cancer vaccines, including lack of
tumor specificity and poor immunogenicity [42]. The novel epitopes of self-antigens
generated by the mutations of tumor cells are so-called neoantigens or neoepitopes [43].
The main advantage of neoantigens is that the tumor-specific antigen is only present
in cancer cells, thus eliminating the “off-target” toxicity to nonmalignant tissues [44].
Furthermore, the neoantigens are de novo epitopes derived from somatic mutations, which
could circumvent T-cell central tolerance to boost tumor-specific immune responses [45].
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Numerous studies on different cancer vaccines are currently underway. In addition,
the combination of cancer vaccines with other cancer therapy are in clinical trials with the
goal of long-lasting, tumor-specific immunotherapy [46].
1.1.4. Lymphocyte-Promoting Cytokines
Cytokines are molecules that elicit cellular functions by binding to the corresponding
receptors on the surface of the cells, as exhibited by the etymology of the words (“cyto”
meaning “cell” and “kinos” meaning “movement”). Cancer cells and immune cells secrete
cytokines that bind to their corresponding receptors in order to communicate with each
other. In cancer specifically, tumor cells use cytokines to instruct immune cells to create a
tumor microenvironment (TME) that promotes the progression of the tumor. On the other
hand, some cytokines have the opposite role—these cytokines instruct immune cells to
attack cancer cells, and this immunogenic mechanism can be harnessed as a therapy. In
particular, only some lymphocyte-promoting cytokines which are delivered systemically
can be used for cancer immunotherapy. Until now, three cytokines (i.e., IL-2, IFN-α, and
granulocyte-macrophage colony-stimulating factor (GM-CSF)), have been approved by the
FDA for the treatment of several cancer types. For example, the IL-2 cytokine aldesleukin
(Proleukin®) targeting the IL-2/IL-2R pathway was approved for subsets of patients with
kidney cancer and melanoma [47,48]. IFN-α, including IFN-α-2a and IFN-α-2b (Intron A®
and Sylatron®), was approved for subsets of patients with leukemia, sarcoma, lymphoma,
and melanoma [48–51]. In 2020, a new cytokine, GM-CSF, combined with naxitamab-gqgk
(Danyelza), a targeted antibody against the GD-2 pathway, was approved for the treatment
of relapsed/refractory neuroblastoma in the bone or bone marrow [52]. The clinical use of
these cytokines marked a milestone in cancer immunotherapy. However, some problems
still remain in cytokine-based immunotherapy. For example, high doses of IL-2 and IFN-α
caused high toxicity, whereas low-doses of IL-2 had a low response rate [48,53–55]. Even
so, cytokines such as IL-12, IL-15, and IL-21 combined with other approaches (such as ICI
therapy and chemotherapy) are currently in clinical trials. These combination approaches
present a more favorable opportunity to achieve an optimal cytokine balance [56].
1.2. Cancer Chemoimmunotherapy
Chemotherapy has served as the standard-of-care cancer treatment for a long time. It has
been shown that the combination of chemotherapy and immunotherapy is a potential strategy
in cancer therapy due to the synergistic effects on the TME. However, chemoimmunotherapy is
not simply the result of combining chemotherapy and immunotherapy, since the mechanisms
of these therapeutic modalities could influence each other. Most chemotherapeutic agents
are cytotoxic agents with non-specific targets, which may not only cause the death of cancer
cells but also influence the proliferation of most cell types in the human body [57]. The direct
effects of chemotherapy on cancer cells (“on-target” effects) might elicit anticancer immune
responses, whereas the “off-target” effects on the host immune cells might have implications
for anticancer immunosurveillance [58]. The chemoimmunotherapy is either synergistic or
complementary, depending on whether chemotherapeutic agents are immune-promoting or
immune-suppressing. We summarize clinical chemoimmunotherapy strategies to illustrate
the combination mechanisms in Table 1.
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Table 1. Representative clinical trials of chemoimmunotherapy.
Chemotherapeutic Agents Immunotherapeutic Agents Cancer Type Phase Identifier
Cisplatin (CP) + docetaxel
(DTX) Dendritic cells Head and neck cancer I NCT01149902
Irinotecan + temozolomide GM-CSF Neuroblastoma I NCT03189706
CP Pembrolizumab Ovarian cancer recurrent I/II NCT03734692
Fulvestrant + DTX Trastuzumab, pertuzumab HER2-positive breast cancer, ER-positivebreast cancer I/II NCT02345772
CP, doxorubicin (DOX),
etoposide Epratuzumab
Recurrent childhood acute lymphoblastic
leukemia I/II NCT00098839
Carboplatin, DOX Tocilizumab + IFN-α-2b Recurrent ovarian cancer I/II NCT01637532
DTX Cemiplimab Prostate cancer metastatic II NCT03951831
Carboplatin + etoposide +
lamivudine Atezolizumab Extensive-stage lung small cell carcinoma II NCT04696575
CHOP (CP + DOX +
vincristine + prednisone) Alemtuzumab Lymphoma, T cell, peripheral II NCT01679860
CHOP Rituximab Lymphoma, large B cell II NCT03536039
Carboplatin GM-CSF, rIFN-γ Ovarian cancer, fallopian tube cancer,peritoneal cancer II NCT00501644
Cisplatin, carboplatin,
etoposide Durvalumab, ceralasertib Extensive-stage small cell lung cancer II NCT04699838
Cisplatin + gemcitabine Atezolizumab Bladder cancer II NCT04630730
Bendamustine +
mitoxantrone Rituximab Follicular lymphoma II NCT01523860
Pemetrexed +
carboplatin Durvalumab Non-small cell lung cancer, metastatic II NCT04163432
Bendamustine Obinutuzumab Mantle cell lymphoma, non-Hodgkinlymphoma II NCT03311126
Fludarabine + CP Ofatumumab B-cell lymphoid leukemia II NCT01762202
Cabazitaxel + carboplatin Nivolumab + ipilimumab Metastatic prostate neuroendocrinecarcinoma, metastatic prostate cancer II NCT04709276
Fludarabine + CP Ofatumumab Small lymphocytic Lymphoma, chroniclymphocytic leukemia II NCT01145209
5-Fluorouracil IFN Colon cancer stage III III NCT00309530
Fludarabine + CP Rituximab Chronic lymphocytic leukemia III NCT03836261
DHAP (dexamethasone +
cytarabine + CP) Ofatumumab, rituximab
Relapsed or refractory diffuse large B cell
lymphoma III NCT01014208
Venetoclax, ibrutinib Rituximab, obinutuzumab Chronic lymphocytic leukemia III NCT02950051
Carboplatin + paclitaxel Nivolumab Non-small cell lung cancer III NCT04564157
Immunogenic cell death (ICD), which is characterized by the secretion of damage-
associated molecular patterns (DAMPs), is a widely known mechanism to stimulate the
immune response through activation of APCs and consequent activation of a specific
T-cell response [59,60]. Some cytotoxic chemotherapeutic agents, such as anthracyclines,
cyclophosphamide, oxaliplatin (OXA), and bortezomib, can induce ICD effects by increas-
ing the antigenicity of cancer cells [61–64]. Combination of ICD inducers with immune
therapeutics might induce a synergistic effect to enhance immunotherapy. For example,
doxorubicin (DOX) combined with the indoleamine 2,3-dioxygenase (IDO-1) inhibitor
indoximod (IND) exhibited a synergistic antitumor response that was superior to a DOX-
only treatment in 4T1 orthotopic tumor-bearing mice [65]. A combination of paclitaxel
(PTX) and anti-PD-1 antibody activated the antitumor response by the ICD effect and
suppressed the immune escape, resulting in a synergistic antitumor effect in a mouse
melanoma model [66]. The apoptotic cells and cell fragments induced by the ICD effect
of chemotherapeutic agents are also regarded as a potential source of cancer vaccine im-
munogen with personalization between individuals. Researchers utilized the concept of
in situ vaccination to inject DOX intratumorally to generate immunogenic apoptotic frag-
ments/cells and then combined them with a CpG oligodeoxynucleotides (CpG) adjuvant
for in situ chemoimmunotherapy [67].
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Multiple chemotherapeutic agents can interact with immune cell subsets directly to
activate antitumor responses. Depletion of immunosuppressive cells is one of the positive
effects of these chemotherapeutic agents. For example, low-dose 5-fluorouracil (5-FU)
chemotherapy inhibited lung-accumulating myeloid-derived suppressor cells (MDSCs)
in tumor-bearing mice [68]. Low-dose cyclophosphamide has been shown to deplete
tumor-infiltrating regulatory T cells (Treg) cells in mice [69,70]. Some chemotherapeutic
agents also modified the phenotype of immune cells to improve antitumor response. The
repolarization of tumor-promoting M2-type tumor-associated macrophages (TAMs) into
the tumor-suppressing M1 type has been observed in mice upon administration of PTX [71].
Combination of these chemotherapeutic agents with other immune activators seems to
provide enhanced antitumor immune response in the TME.
In addition to the effects on cancer and immune cells directly, some conventional
chemotherapeutic agents may cause some “off-target” side effects on the whole-body
immune response involving multiple pathways, such as gastrointestinal toxicity affecting
the gut microbiota and upregulation of systemic immunosuppressive factors [72,73]. Some
novel chemotherapeutic agents such as molecularly targeted agents are also involved in
immunosuppression caused by hypoxia after treatment [74,75]. Compared with chemother-
apy alone, the combination of these chemotherapeutic agents with immune modulators,
which reverses the immunosuppressive microenvironment and improves chemotherapeu-
tic effect, is regarded as a complementary mechanism to enhance antitumor effect. For
example, the combination of anti-PD-1 antibody, the CXCR-4 inhibitor AMD3100, and
sorafenib showed a superior antitumor effect compared to anti-PD-1 antibody combined
with sorafenib alone. This was because AMD3100 prevented the polarization toward an
immunosuppressive microenvironment after the sorafenib treatment [74,76]. Finally, CpG
oligodeoxynucleotides could reverse the immunosuppression caused by treatment with
5-FU in murine hepatoma to inhibit tumor growth [77].
In summary, combination of chemotherapeutic agents with immunotherapy can
augment antitumor response in the TME, thus improving cancer treatment.
2. Immune Microenvironment in Cancer: The Glioblastoma Paradigm
Cancer is one of the leading causes of death in the United States (U.S.), fueling the
urgency to develop new and efficient cancer treatments. Especially for cancers of the
brain or nervous system, mortality rates have been increasing over the past few years
(NCI Cancer Trends Progress Report). Of these diagnoses, glioblastoma (GBM), a very
aggressive brain tumor, has one of the highest mortality rates. GBM has an average
overall survival of 15 to 21 months after first diagnosis and a 5-year survival rate of
less than 5%, which is the lowest among other central nervous system (CNS) tumors
and second lowest out of all other types of cancer [78–80]. These numbers have slightly
improved as existing therapies such as surgical removal, chemotherapy, and radiotherapy
are used in conjunction with new therapeutic advances such as the use of oncolytic viruses,
dendritic cell vaccines, tumor-treating fields, and immunotherapy [81–85]. However, these
treatment options have failed to effectively treat GBM patients as they often result in
eventual relapse or death. A facet of GBM that contributes to its dismal prognosis is
the immunosuppressive nature of the GBM TME. Although functional lymphatic vessels
in the brain allow the transport of immune cells from the cerebrospinal fluid, and by
extension, the deep cervical lymph nodes, immune cells are unable to have an effect of
the tumor because of the nature of the TME. The immunosuppressive effect of the TME is
created and maintained using two mechanisms. In the first, the GBM immune environment
promotes protumor activity by promoting regulatory T-cell [86] or MDSC [87] activity by
inducing the recruitment of those tumor-suppressive cells to the tumor site and polarizing
TAMs toward the immunosuppressive M2 phenotype [88]. Second, the GBM immune
environment suppresses antitumor activity by inhibiting the activation and recruitment
of cytotoxic T cells and preventing the migration of tumor-infiltrating T cells [89] and NK
cells [90] to the tumor site, among other mechanisms.
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Possible chemoimmunotherapeutic approaches to GBM must aim to modulate the
immunosuppressive TME that allows GBM to progress. Specifically, these chemoim-
munotherapeutic approaches must target cytokines, their binding receptors, and other
associated cells that contribute to immunosuppression. Cytokines can be categorized into
two broad groups based on their overall effect on the tumor and TME, and then further
divided into subgroups based on the specific location and targets of these effects:
(1) Protumor cytokines: Cytokines exhibit protumor effects through multiple possible
mechanisms.
a. Cytokines change the activity of protumor cells including regulatory T cells and
MDSCs. IL12 can change the expression profile of proinflammatory cytokines
by TAMs [91]. Chemokine (C-X-C motif) ligand 16 (CXCL16)/chemokine
receptor 6 (CXCR6) signaling elicits anti-inflammatory effects in glioma by
driving microglia polarization [92].
b. Cytokines instigate the lymphatic migration of immune-tolerogenic APCs.
Although DCs are responsible for immunogenicity via priming, they are also
responsible for immunologic tolerance [93,94]. Particularly, DCs in the presence
of tumor growth factor (TGF) beta-1 can transform cytotoxic T cells into Treg
cells [95].
c. Cytokines released from tumor cells can recruit tumor-suppressive cells to the
tumor site. IL33 produced by tumor cells can recruit TAM [96]. C-C motif
chemokine ligand 2 (CCL2) produced by CXCR4+ tumor-associated microglia
M1 can recruit the CC chemokine receptor 4 (CCR4)+-expressing Treg cells and
MDSCs to gliomas [97,98]. CCL2 is also known as the CCR4 ligand that is
secreted from GBM and is responsible for Treg accumulation in GBM [99].
d. Cytokines can create tumor-immune tolerogenic response at the tumor-draining
lymph nodes. Glioma cells secrete IDO, which prevents the activation of
CD8/CD4+ cells by increasing Treg activity [100,101]. Cytotoxic T-lymphocyte-
associated protein 4 (CTLA4) on T cells suppresses the activation of CD4+ and
CD8+ T cells [102].
(2) Antitumor cytokines: Conversely, cytokines also exhibit antitumor activity.
a. Cytokines induce immunologic response at the tumor site. IL12 activates T
memory and effector cells [103]. IL27 increases NK cell activation and cyto-
toxicity against mammary tumor murine models [104]. Calreticulin, antigen
expressed on the surface of cancer cells, can also activate DC phagocytosis.
However, calreticulin normally resides inside of the cells, and needs to be
translocated to the surface of the cancer cells to be detected by DCs [105].
b. Cytokines recruit immunologic APCs. As stated previously, CCL2 can recruit
tumor-associated microglia and MDSCs in the glioma TME, but also is known
to induce the migration of antigen-presenting DCs in sarcoma and mammary
carcinoma [106].
c. Cytokines recruit cytotoxic T cells or/and NK cells. IL33 recruits CD4+ T helper
cells and FOP3+ Treg cells to the tumor site [96]. CXCL10 recruits NK cells to
the tumor site [107].
d. Cytokines can also induce an immunologic response at tumor-draining lymph
nodes. The stimulator of interferon gene (STING) receptor and pathway on
DCs is responsible for the production of type I and II IFNs, which activate T
cells at tumor-draining lymph nodes [108].
In the case of GBM, immunotherapy has failed to show a significant effect [109]. It is
believed that immunotherapy lacks efficacy in GBM due to the absence of an antitumor
immunologic system, the presence of a protumor or immunosuppressive system, or both
(Figure 2). A possible solution to augment the effects of immunotherapy in brain tumors
may be the combinatorial use of chemo- and immunotherapy to: (1) Compensate for
the absence of antitumor immune cells. Chemotherapy can be toxic to cancer cells and
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thereby create tumor-associated antigens that can be presented to naive antitumor T cells
and transform the naive cells into CD8+ cytotoxic T cells; (2) Recruit immunologic cells.
Chemotherapy can induce the secretion of promigratory factors from immune cells, and
these promigratory factors can promote the recruitment of antitumor immune cells (i.e.,
cytotoxic T cells) to the tumor site; and (3) Reduce the activity of immunosuppressive
cells. Chemoimmunotherapy can decrease the activity of immunosuppressive Treg cells
or MDSCs. Modulating this immune system can involve manipulating the activity of
cytokines in the GBM TME. However, the GBM TME consists of a complex network of
cytokine interactions. For example, CCL2 has been shown to induce the migration of DCs
and to possess an immunogenic function and activate macrophages in conjunction with
CXCL12 [106,110]. At the same time, CCL2 is known to be secreted from microglia and
macrophages in the presence of CCL20 [110]. CCL2 shows not only an immunogenic effect
but also an immunosuppressive effect. CCL2 promotes the recruitment of immunosuppres-
sive Treg and MDSCs, which can potentially suppress the antitumor immunologic activity
of other immune cells [97]. Therefore, manipulating this network of cytokines in the GBM
TME via chemoimmunotherapy requires technologies that comprehensively address the
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Figure 2. List of clinical challenges that need to be addressed by chemoimmunotherapy for glioblas-
toma (created with BioRender.com).
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3. Lipid-Based Nanoparticles in Cancer Chemoimmunotherapy
Nanotechnology has attracted extensive attention in cancer therapy due to certain
advantages [111]. For example, nanoparticles, including polymeric micelles, lipid-based
nanoparticles, gold nanoparticles, and inorganic nanoparticles, are being widely used to
deliver various therapeutic agents such as small molecules (either hydrophilic or hydropho-
bic), proteins, and genes for cancer therapy. These nanoparticles can deliver therapeutic
agents to specific cells and organelles through either passive targeting mechanisms such
as the enhanced permeability and retention (EPR) effect or active targeting mechanisms
mediated by targeting ligands [112]. Due to the superior targeting effect of nanoparticle-
based delivery systems to the tumor tissue and tumor cells, the distribution of therapeutics
in the body is altered and consequently “off-target” side effects on the normal tissue
can be decreased. These advantages will provide more opportunities for the application
of nanoparticles in cancer chemoimmunotherapy to improve combination therapy with
reduced side effects.
In particular, lipid-based nanoparticles possess attractive biological and versatile
characteristics, including biocompatibility, biodegradability, and the ability to entrap both
hydrophilic and hydrophobic therapeutics [113–115]. Moreover, surface properties (e.g.,
charge and decorating with targeting ligands) of lipid-based nanoparticles can be easily
modified via varying lipid components or surface modification. Currently, lipid-based
nanoparticles for cancer chemoimmunotherapy in preclinical studies include liposomes,
nanodiscs, and lipid-based hybrid nanoparticles. Recent examples of lipid-based nanoparti-
cles in cancer chemoimmunotherapy are listed in Table 2. Next, we will introduce different
kinds of lipid-based nanoparticles and their advantages and disadvantages.
Table 2. Preclinical studies of lipid-based nanoparticles in cancer chemoimmunotherapy.
Formulation Chemotherapy Immunotherapy Cancer Type Administration Route Ref
Liposomes
PEGylated liposomes Doxorubicin Alendronate Breast cancer i.v. [116]
Doxorubicin P5 peptide Breast cancer i.v. [117]
Doxorubicin E75 immunogenic
peptide
Breast cancer i.v. [118]









Doxorubicin Indoximod Breast cancer i.v. [65]








Paclitaxel PD-L1 antibody Melanoma i.v. [122]
Choline phosphate
lipid-based liposomes












Paclitaxel HY19991 Metastatic breast
cancer
i.v. [126]
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Table 2. Cont.
Formulation Chemotherapy Immunotherapy Cancer Type Administration Route Ref
Immunoliposomes Irinotecan JQ1 Colorectal cancer i.v. [127]






















Colorectal cancer i.v. [133]
Nanodiscs






Colon carcinomas Intra-tumoral [136]











IL-2 Melanoma i.v. [139]






















i.v., intravenous injection; s.c., subcutaneous injection; i.p., intraperitoneal injection; 5-FU, Fluorouracil; siRNA, small interfering RNA.
3.1. Liposomes
Liposomes, consisting primarily of phospholipids and cholesterol, are nanosized vesi-
cles with demonstrated advantages in biocompatibility and enhanced targeted payload
delivery with minimal toxicity. Amphiphilic phospholipids self-construct into a spherical
lipid bilayer structure with their lipophilic tails, creating an environment for hydropho-
bic drugs to be encapsulated. On the other hand, hydrophilic heads of phospholipids
assemble into an exterior surface and an aqueous core that can enclose hydrophilic agents.
The encapsulation of various therapeutic agents into liposomes can occur through either
charge–charge interactions or interaction with chemical linkers on the liposomal exterior.
Importantly, the encapsulation of therapeutics within different liposomal compartments
allows safe and targeted drug delivery, since the liposomes can protect the enclosed cargos
from degradation by the immune system while carrying them across biological membranes
that the free drugs (nonencapsulated in liposomes) are often incompatible with. Lipo-
somes, enabling the drug delivery of both hydrophilic and lipophilic therapeutic agents
while preserving their efficacy, are among the most successful nanotechnology-based drug
products in cancer therapy. Since PEGylated liposomal DOX (Doxil®) became the first
FDA approved nano-drug in 1995, more than six liposomal drugs have been approved
by the FDA for use in cancer therapy. Building upon the success of liposomal drugs
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in chemotherapy, liposomes have been employed as one of the most attractive delivery
vehicles in chemoimmunotherapy.
3.1.1. Combinatorial Use of Liposomal Drugs and Immunotherapeutic Agents
Combining liposomal drugs with immunotherapeutic agents is a simple and accept-
able method to accomplish chemoimmunotherapy. Some approved liposomal drugs, such
as Doxil®, Taxol®, LipoTaxen®, and Onivyde®, have been used in chemoimmunotherapy.
For example, a combination of Doxil® with an immunostimulatory cytokine recombinant
IL-18 (SB-485232) is currently in a clinical trial (NCT00659178). The phase I study showed
that SB-485232 at a 3 mg/kg dose level in combination with Doxil® was safe and bio-
logically active for the treatment of ovarian cancer. This combination warranted further
study in a phase II trial [144]. Another combination therapy based on Doxil® is also in a
phase I clinical trial (NCT00887796). The NY-ESO-1 vaccine, decitabine, and Doxil® were
administrated sequentially in 12 patients with relapsed epithelial ovarian cancer (EOC).
The results showed that EOC cells treated with the combination of decitabine and Doxil®
promoted NY-ESO-1 antigen-restricted CTL recognition of EOC cell lines, and the effect of
drug treatment on NY-ESO-1 expression was long-lasting [145]. Similarly, the improved
cancer therapeutic effect was observed in a combination of Doxil® and motolimod (a novel
Toll-like receptor 8 agonist) in a phase I study (NCT01294293). The evidence of antitumor
activity was observed at the 2.5 and 3.0 mg/m2 dose levels, and 3.0 mg/m2 was selected
as the recommended phase II dose. Doxil® plus motolimod costimulated antitumor innate
and adaptive immunity mechanisms to achieve an enhanced antitumor effect [146].
There are other preclinical liposome-based chemoimmunotherapeutics, in which
immunotherapeutic agents are encapsulated in liposomes to improve the delivery of these
agents along with the use of liposomal drugs. Mahmoud et al. proposed a P5 peptide and
Doxil® combination strategy for HER2+ breast cancer treatment [117]. The results revealed
that Doxil® administrated before the immunotherapy could reduce the population and
functions of MDSCs and enhance the subsequent immunotherapy, resulting in elevated
CD4+ (p < 0.01) and CD8+ lymphocyte (p < 0.001) populations as well as IFN-γ production
(p < 0.001). Compared to the free peptide and doxorubicin, Doxil® plus liposomal P5
showed a decreased effect on MDSCs and tumor growth, which could be beneficial in breast
cancer treatment. In another study, the combination of Doxil® with liposomes containing
another E75 immunogenic peptide (Lip-Pep) also exhibited enhanced antitumor effect in
breast cancer [118]. It was shown that Doxil® induced immune responses more effectively
than the nonliposomal DOX. In the case of chemoimmunotherapy, the combination of
Lip-Pep and Doxil® was more effective and had a higher survival rate than the combination
of Lip-Pep and nonliposomal DOX (p < 0.001) [118].
Combination of liposomal drugs with immunotherapeutic agents or liposomal im-
munotherapeutics is an efficient way to achieve enhanced chemoimmunotherapy with
long-lasting response, high survival rate, and low toxicity. It is worth mentioning that
sequential administration of chemo- and immunotherapeutics was used in some studies.
Therefore, the proper dosing sequence of chemotherapy and immunotherapy is a key factor
that needs to be taken into consideration for improved therapeutic effect.
3.1.2. Immunoliposomes
Immunoliposomes, the structural combination of liposomes and antibodies, represent
a new strategy for chemoimmunotherapy. Immunotherapeutic antibodies are decorated
on the surface of liposomes and used with chemotherapeutic agents encapsulated in the
liposomes. This two-in-one strategy may lead to enhanced chemoimmunotherapy with
reduced toxicity. For example, Gu et al. developed a PD-L1 mAb modified pH-sensitive
liposome for the combinatory use of docetaxel (DTX) and PD-L1 antibody for melanoma
therapy. These immunoliposomes exhibited effective tumor inhibition and prolonged
survival due to the synergistic effect of the activation of tumor-specific CD8+ T cells and
highly selective tumor killing [130]. In recent years, novel immunoliposomes have been
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developed for chemoimmuntherapy. For example, a phosphatidyl choline reversed choline
phosphate lipid (CP-Lip) was synthesized and modified with a PD-L1 antibody (CP-αPDL),
as shown in Figure 3 [123]. DOX was loaded into the liposomes to achieve codelivery
of DOX and αPDL (Dox@tCP-Lipos) to melanoma cells. Impressively, CP-Lip was able
to insert into and interact strongly with the cell membrane, resulting in largely reduced
fluidity and functionality of the membrane. As a result, the tumor was 100% suppressed
after the treatment with Dox@tCP-Lipos.
Despite a large number of preclinical studies supporting the advantages of immuno-
liposomes, few immunoliposomes have eventually reached clinical trials. Some factors,
such as lipid type, conjugation bond, as well as the combination ratio of chemotherapeutic
and antibody, need to be optimized to enable the clinical translation of this new type of
























Alkylated NLG919  (aNLG), an  IDO1  inhibitor, and oxaliplatin‐prodrug  (Oxa(IV)) were 
coencapsulated in PEGylated liposomes as a bifunctional liposome (NLG/Oxa(IV)‐Lip) for 
colorectal cancer therapy. NLG/Oxa(IV)‐Lip not only released cytotoxic oxaliplatin inside 
Figure 3. Schematic showing the chemical structure of phosphatidyl choline reversed choline phos-
phate lipid (CP-Lip) and the endocytosis mechanism of lipos mes codelivery of DOX and αPDL
Dox@tCP-Lipos. Reproduced from [123], Chemical Communications, 2021.PC-Lip, phosphatidyl
choline lipid; CP-Lip, choline phosphate lipid; DOX·HCl, doxorubicin hydrochloride; PD-L1, Pro-
grammed death-ligand 1; αPDL, PD-L1 antibody.
3.1.3. Codelivery of Chemo- and I munotherapeutics in Liposomes
Two or more therapetics can be coencapsulated in one liposome and simultaneously
delivered to the TME. Codelivery of chemo- and immunotherapeutics via the same lipo-
some limits the delivery of both drugs into the same type of cells, which is particularly
beneficial for immunotherapeutic agents with their target site in tumor cells. For example,
the IDO inhibitor is a commonly used immunotherapeutic agent that targets tumor cells.
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Alkylated NLG919 (aNLG), an IDO1 inhibitor, and oxaliplatin-prodrug (Oxa(IV)) were
coencapsulated in PEGylated liposomes as a bifunctional liposome (NLG/Oxa(IV)-Lip)
for colorectal cancer therapy. NLG/Oxa(IV)-Lip not only released cytotoxic oxaliplatin
inside the reductive cytosol to trigger immunogenic cell death (ICD) of cancer cells, but also
efficiently retarded the degradation of tryptophan to immunosuppressive kynurenine via
the NLG919-mediated inhibition of IDO1. NLG/Oxa(IV)-Lip showed synergistic antitumor
effects in both subcutaneous and orthotopic CT26 tumor models [119]. In another study,
DOX and indoximod (IDO inhibitor) were coencapsulated into bifunctional liposomes
for the treatment of breast cancer. The chemoimmunotherapy mechanisms are illustrated
in Figure 4 [65]. With the development of immunotherapy, more tumor-targeting im-
munotherapy will be investigated. It is anticipated that bifunctional liposomes will be


































Figure 4. Schematic to explain breast cancer immunotherapy by codelivery of an immunogenic
cell death stimulus plus an inhibitor of the IDO-1 pathway. Adapted with permission from [65],
ACS Nano 2018. https://pubs.acs.org/doi/full/10.1021/acsnano.8b05189 22 Febru ry 2021. CRT,
calreticulin; BC, breast cancer; HMGB-1, high mobility group box 1 protein.
3.2. Nanodiscs
Nanodiscs, composed of a lipid bilayer of phospholipids with the hydrophobic edge
screened by two amphipathic proteins, also referred to as membrane scaffolding proteins
(MSP), are a synthetic model membrane system. In some nanodiscs, the MSP is modified
apolipoprotein A1 (apoA1), which is the main constituent in high-density lipoproteins
(HDL). The structure of nanodisc is similar to discoidal HDL, which mimics a more native
environment than liposomes and micelles. This biomimicking delivery system seems to
be more effective in immunotherapy. Schwendeman’s group have done a lot of work
on nanodisc-based chemoimmunotherapy. Initially, they developed an HDL-mimicking
nanodisc coupled with a neoantigen (Ag peptide) and adjuvant (CpG) to draining lymph
nodes for vaccination. The nanodisc elicited up to 47-fold greater frequencies of neoantigen-
specific CTLs than soluble vaccines and 31-fold greater than the adjuvant (i.e., CpG in
Montanide) used in clinical trials. These findings supported a new powerful approach
for cancer immunotherapy [147]. The same group also employed nanodiscs for chemoim-
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munotherapy. They found that chemoimmunotherapy based on the combination of DOX-
carrying nanodiscs and anti-PD1 induced complete regression of established CT26 and
MC38 colon carcinoma tumors in 80–88% of animals and protected survivors against tu-
mor recurrence [134]. Recently, they developed synthetic high-density lipoprotein (sHDL)
nanodiscs loaded with CpG together with DTX for the chemoimmunotherapy of GBM
(Figure 5) [135]. DTX-sHDL-CpG nanodiscs exhibited improved therapeutic effect with
no overt “off-target” side effects. Furthermore, the combination of DTX-sHDL-CpG treat-
ment with radiation (IR) resulted in tumor regression and long-term survival in 80% of
GBM-bearing animals. In another study, Han et al. developed a lipophilic AS1411 aptamer-
immunoadjuvant CpG fused sequences (Apt-CpG-DSPE)-modified HDLs for coloading
of CpG and DOX (imHDL/Apt-CpG-Dox) for the treatment of lung cancer [137]. The
imHDL/Apt-CpG-Dox was endocytosed into tumor cells as mediated by the recognition
of AS1411 and nucleolin (sequential module II), translocating DOX to the nucleus and
enabling tumor ablation and antigen release. The liberated CpG motif further evoked
antigen recognition, induced vast secretion of proinflammatory cytokines, and potentiated
host antitumor immunity. Although nanodiscs have demonstrated a huge potential for
chemoimmunotherapy, there are some issues (such as the contact angle between nanodisc





































Figure 5. Immune-mediated antiglioma mechanism of docetaxel-loaded CpG-sHDL nanodiscs.
Reproduced with permission from [135], ACS Nano 2018. CpG, CpG oligodeoxynucleotides; sHDL,
synthetic high-density lipoprotein.
3.3. Lipid-Based Hybrid Nanoparticles
Lipid-based hybrid nanoparticles with versatile structures (e.g., core–shell-structured
hybrid nanoparticles with either a lipid core or shell) are attractive for chemoimmunother-
apy. Some inorganic nanoparticles with a lipid shell have been developed for efficient
therapeutic loading. For example, Kong et al. developed lipid-coated biodegradable hollow
mesoporous silica nanoparticles (dHMLB) with coencapsulation of all-trans retinoic acid
(ATRA), DOX, and IL-2 (A/D/I-dHMLB) for chemoimmunotherapy [139]. A/D/I-dHMLB
exhibited a much higher tum r inhibitory rate (84.8 ± 13.0%) compared to that of any
two-agent coloaded nanoparticles and a ixture solution f th e agents. Simil rly, Nano-
Folox-encapsulated folinic acid (FnA) and oxaliplatin (OXA) w re combined with 5-FU
and anti-PD-L1 mo clonal antibo y, resulting in decreased liver metastases in mic [140].
Nano-Folox was formed by a nanoprecipitate (C26H35N9O7Pt) core and an aminoethyl
anisamide-targeted PEGylated lipid shell as shown in Figure 6. Compared to FOLFOX (the
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standard treatment of colorectal cancer), the significantly stronger chemoimmunotherapeu-





Figure 6. Schematic of Nano-Folox formulated in microemulsions using a nanoprecipitation tech-
nique. Reproduced with permission from [140], ACS Nano 2020. DOPA, 1,2-dioleoyl-sn-glycero-3-
phosphate; DOTAP, 1,2-dioleoyl-3-trimethylammonium propane; DSPE-mPEG2000, 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine- polyethyleneglycol-2000; AEAA, aminoethyl anisamide.
A lipid core of hybrid nanoparticles has also been used for loading drugs for chemoim-
munotherapy. Zhang et al. developed twin-like core–shell nanoparticles (TCNs) for
synchronous biodistribution and targeted delivery of sorafenib (SF) and IMD-0354 (an
TAM repolarization agent) to cancer cells and TAMs to enhance tumor-localized chemoim-
munotherapy, respectively [141]. The cationic lipid-based nanoparticles served as the
core for loading different therapeutics, and they were modified using the same shell (O-
carboxymethyl-chitosan) to achieve synchronous biodistribution (Figure 7). The results of
in vivo antitumor effect and phenotype analysis of TAM in tumor tissues demonstrated
that TCNs exhibited a superior synergistic antitumor effect and polarization ability of
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Figure 7. Schematic of twin-like core–shell nanoparticles (CMCS/SF-CLN + CMCS/M-IMD-
CLN) for synchronous biodistribution and cell-specific targeted delivery to enhance chemoim-
munotherapy. Adapted from [141]. Nanoscale 2019. SF, sorafenib; DOPE, 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine; M-DOPE, mannose-DOPE; CMCS, carbox methyl chitosan; CLN, ationic
lipid-based nanoparticles; , IMD0354, a selective IKKβ inhibitor.
In addition to core–shell-structured hybrid nanoparticles, other lipid composite nanopar-
ticles have also been investigated for chemimmunotherapy. Huang et al. developed cationic
lipid-assisted nanoparticles (CLANs) for codelivery of IDO1 siRNA and OXA for the treatment
of orthotopic pancreatic cancer [142]. The CLANs were formed using a double emulsion sol-
vent evaporation technique [148]. siRNA was successfully delivered to both tumor-draining
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lymph nodes and tumor tissues in the presence of cationic lipids. The contemporaneous
administration of OXA and CLANs IDO1 could achieve synergetic antitumor effects via
promoting DC maturation, increasing tumor-infiltrating T lymphocytes as well as decreasing
the number of regulatory T cells in a subcutaneous colorectal tumor model. Recently, a
novel hybrid nanoparticle was designed and used for the codelivery of GM-CSF and DTX in
metastatic peritoneal carcinoma (mPC) therapy [143]. This hybrid nanoparticle was formed
by genetically engineered exosomes and thermosensitive liposomes (gETL NPs), as shown in
Figure 8. The gETL NPs administrated via intravenous injection could efficiently penetrate
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Figure 8. Schematic of the synthesis and a plication of genetically engine red exosomes and ther-
osensitive liposomes for the treatment of metastatic peritoneal carcinoma. Adapted from [143],
Advanced Science, 2020. gETL NPs, genetically engineered exosomes-thermosensitive liposomes
hybrid nanoparticles; HIPEC, hyperthermic intraperitoneal chemotherapy; TAMs, tumor-associated
macrophages; gExos, gExos, genetically engineered exosomes; TLs, thermosensitive liposomes; MPS,
mononuclear phagocytic system.
The lipid-based hybrid nanoparticles preserve the advantages of lipid nanoparticles
yet provide a more flexible structure, which could be advantageous in chemoimmunother-
apy. However, the complicated structure and fabrication procedures will impede the
clinical translation of these hybrid nanoparticles.
4. Challenges and Future Perspectives
he oi unotherapy has been increasingly important in cancer therapy due to
adv ntages such as high i mune responsiveness, widened a plications in di ferent cancer
types, as e l as long-ter therapeutic e fect. Nanotechnology-base deli er s ste s, i
particular lipid-based nanoparticles, a e bee se to ac ie e e citi c r i
che oi t r tc i precli ic l resear , e to their ability to reduce “o f-
target” side e fects and deliver thera e tics (s c as siR and protei s) to specific target
sites hile preserving their biological activity. However, the clinical translation of lipid-
based nanoparticles for chemoimmunotherapy is still limited because some challenging
issues are yet to be resolved. First of all, the design of lipid-based nanoparticles needs
to be simplified in order to enable large-scale production. Some multifunctional lipid-
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based nanoparticles contain novel materials. The safety of these novel materials is yet
to be studied. Secondly, the combination therapy requires a proper ratio and synergistic
index of chemo- and immunotherapeutics, which need to be well controlled when using
codelivery systems. Since some chemotherapeutic and immunotherapeutic agents have
a narrow therapeutic window for cancer combination therapy, it is important to control
the release amount and ratio of two types of therapeutic agents in the TME to achieve
the desired synergistic effect. For example, DOX can cause an ICD effect at a lower
concentration. When combining DOX with other immunotherapeutic agents based on
the ICD effect, a low dose of DOX should be considered. Thirdly, some novel synthetic
lipid-based nanoparticles may be immunogenic, thus resulting in side effects or immune
response in the TME. Lastly, the mechanism of some chemoimmunotherapy strategies is
still unknown. The delivery and dosing sequence of the combinatorial agents is another
important factor that needs to be taken into consideration for improved anticancer effect.
Typically, immunotherapeutic agents needed to be dosed two or more times with a long
time interval to stimulate the immune response. This is not in accordance with the dosing
frequency of some chemotherapies, which require the administration of chemotherapeutic
agents frequently. Therefore, designing a proper delivery system which can codeliver
combinational agents with different release behaviors is important. The delivery sequence
is another factor to be considered in combination therapy. In some cases, chemotherapeutic
agents need to be delivered prior to immunotherapy since the chemotherapy may trigger
certain immune responses. On the other hand, if immunotherapy is needed to stimulate
some immune response prior to chemotherapy, a codelivery system with delayed release
of chemotherapeutic agents may be desirable. Combinations of immunotherapy with
multiple therapeutic strategies (e.g., the combination of immunotherapy with radiotherapy
or photothermal therapy as well as diagnosis) are currently being investigated in preclinical
studies and have shown synergistic effects in cancer treatment. Lipid-based nanoparticles
have been used in these novel combination strategies. Building upon the recent success of
RNA vaccine therapies, it is expected that lipid-based nanoparticles could be an efficient
delivery candidate for RNA drugs in cancer therapy. Lipid-based nanoparticles could
enable improved synergistic effects of combination therapies in cancer treatment.
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